js","6773","static/chunks/6773-061975b7a13f2526.js","3763","static/chunks/3763-5031c38f7a5044a1.js","4777","static/chunks/4777-7fa79cea095b0267.js","5071","static/chunks/5071-1aaad1643fd0f3d9.js","8631","static/chunks/8631-6612905842e66f05.js","3956","static/chunks/3956-445a540d184d91db.js","7952","static/chunks/7952-ee4e3ac10fbedfda.js","512","static/chunks/512-bcb290eabed856c4.js","7759","static/chunks/7759-79303bb83414620d.js","5422","static/chunks/5422-29b2c0073e365b16.js","2507","static/chunks/2507-ee0144f0fb20ac76.js","8492","static/chunks/8492-f17ab3216fe361f9.js","2785","static/chunks/2785-116580b35f1bb322.js","8368","static/chunks/8368-438d4be7dd683dfc.js","9080","static/chunks/9080-238ac880c12fda6b.js","7072","static/chunks/7072-530245caea10a4c5.js","3192","static/chunks/3192-edaab38c2fdeb6ab.js","3077","static/chunks/3077-c474095a61bd66c9.js","8234","static/chunks/8234-bf699f647ee74353.js","4589","static/chunks/4589-5b05633819f33918.js","229","static/chunks/229-db5ac014176aaf5b.js","5458","static/chunks/app/dashboard/episodes/%5Bid%5D/page-249b9fb0028b9980.js"],"EpisodeRecommend"] 23:T550,

BIO is engaging with President Donald Trump to protect and improve FDA. It’s also hoping biopharmas can dodge tariffs and find paths to modify the Inflation Reduction Act and reinstate pediatric priority review vouchers. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin delivers takeaways from his conversation with John Crowley, CEO of the industry trade group.
BioCentury’s editors also discuss how autoimmune CAR T companies are competing for resources and the end-to-end radiopharma ambitions of Telix Pharmaceuticals. A 2023 landscape on the radiopharma space can be found here.

View full story: https://w

Ep. 285 - BIO's Trump 2.0 Plan. Plus: Autoimmune CAR Ts & Telix's Radiopharma Play

BioCentury This Week